Drug intelligence / Profile preview

unengineered NK cells

Development stage
Unknown
Modality
CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

Unengineered NK cells are natural killer cells that have not been genetically modified to express chimeric antigen receptors (CARs) or other exogenous proteins. These cells are typically isolated from allogeneic sources, such as peripheral blood or umbilical cord blood, and expanded ex vivo before being infused into patients as a form of adoptive cell therapy. They rely on their innate repertoire of activating and inhibitory receptors, including killer cell immunoglobulin-like receptors (KIRs), NKG2D, and natural cytotoxicity receptors (NCRs), to recognize and eliminate malignant or virally infected cells. In clinical and preclinical development, unengineered NK cells are frequently used as a standalone immunotherapy or as a critical control arm to benchmark the enhanced specificity, persistence, and anti-tumor activity of engineered cell therapies like CAR-NK cells.

Other names
unmodified NK cellsnon-engineered NK cellsprimary NK cellswild-type NK cells
02

Targets

MICB (Major histocompatibility complex class i-related protein B)NKG2DL (NKG2D ligand family)ULBP (ULBP family)

Beyond the preview

Go deeper on unengineered NK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on unengineered NK cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call